Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment

Abstract

Breast cancer, a multi‐networking heterogeneous disease, has emerged as a serious impediment to progress in clinical oncology. Although technological advancements and emerging cancer research studies have mitigated breast cancer lethality, a precision cancer‐oriented solution has not been achieved. Thus, this review will persuade the acquiescence of proteomics‐based diagnostic and therapeutic options in breast cancer management. Recently, the evidence of breast cancer health surveillance through imaging proteomics, single‐cell proteomics, interactomics, and post‐translational modification (PTM) tracking, to construct proteome maps and proteotyping for stage‐specific and sample‐specific cancer subtyping have outperformed conventional ways of dealing with breast cancer by increasing diagnostic efficiency, prognostic value, and predictive response. Additionally, the paradigm shift in applied proteomics for designing a chemotherapy regimen to identify novel drug targets with minor adverse effects has been elaborated. Finally, the potential of proteomics in alleviating the occurrence of chemoresistance and enhancing reprofiled drugs' effectiveness to combat therapeutic obstacles has been discussed. Owing to the enormous potential of proteomics techniques, the clinical recognition of proteomics in breast cancer management can be achievable and therapeutic intricacies can be surmountable.

Recent Contributions of Mass Spectrometry-Based “Omics” in the Studies of Breast Cancer

“…The group highlighted that a combination of miRNAs rather than single species is preferable for such diagnostic feature developments. Behera (2023) reviewed the promises that proteomes in BC are delivering for insights in drug repurposing and personalized therapeutic regimens . Metabolomic treatment predictors were reviewed by Cardoso (2018) …”

“…Behera (2023) reviewed the promises that proteomes in BC are delivering for insights in drug repurposing and personalized therapeutic regimens. 150 Metabolomic treatment predictors were reviewed by Cardoso (2018). 151…”